Jie Su

Jie Su

Auto-generated profile, based on publicly available information

Jie Su

Department of Biostatistics, the Princess Margaret Cancer Centre/University of Toronto, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2022 in Oral Oncology
Verified
Journal Article
Closed access
OCOlivia Chin
Olivia Chin
LALaila Alshafai
Laila Alshafai
BOBrian O'SUllivan
Brian O'SUllivan
JSJie Su
Jie Su
AHAndrew Hope
Andrew Hope
EYEugene Yu
Eugene Yu

1 April 2017 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
AHAli Hosni
Ali Hosni
SHShao Hui Huang
Shao Hui Huang
WXWei Xu
Wei Xu
JSJie Su
Jie Su
ABAndrew Bayley
Andrew Bayley
AHAndrew J. Hope
Andrew J. Hope
This study examines the characteristics and risk factors of distant metastases following postoperative intensity-modulated radiotherapy in oral squamous cell ca

23 April 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
PWPhilip Wong
Philip Wong
AHAngela Hui
Angela Hui
JSJie Su
Jie Su
SYShijun Yue
Shijun Yue
BHBenjamin Haibe-Kains
Benjamin Haibe-Kains
FLFei-Fei Liu
Fei-Fei Liu
Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas

1 March 2021 in Oral Oncology
Verified
Journal Article
Closed access
JAJohn R. de Almeida
John R. de Almeida
VKValerie Seungyeon Kim
Valerie Seungyeon Kim
BOBrian O’Sullivan
Brian O’Sullivan
DGDavid P. Goldstein
David P. Goldstein
SBScott V. Bratman
Scott V. Bratman
AHAli Hosni
Ali Hosni

21 September 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
WSWei Shi
Wei Shi
MFMackenzie Fijardo
Mackenzie Fijardo
JBJeff Bruce
Jeff Bruce
JSJie Su
Jie Su
WXWei Xu
Wei Xu
FLFei-Fei Liu
Fei-Fei Liu
Purpose: Tumor-infiltrating lymphocytes (TIL) are immune cell populations found within tumors, critical in the antigen-specific host immune response. In this study, we aimed to elucidate the prognostic significance of CD3+, CD4+, and CD8+ TILs in nasopharyngeal cancer (NPC). Experimental Design: Immune cell infiltration was quantified in NPC samples (n = 50) using RNA-sequencing (RNA-seq) data based on rearranged T-cell receptor (TCR) reads and the Estimation of Stromal and Immune cells in malignant tumors using expression data (ESTIMATE) immune score tool. The differential abundances of TIL subset populations were also characterized through IHC staining of formalin-fixed, paraffin-embedded samples from a training cohort (n = 35), which was a subset of the RNA-seq cohort (n = 50). Results: In the RNA-seq cohort, patients with higher rearranged TCR reads experienced superior 5- and 10-year overall survival (OS; P < 0.001), and disease-free survival (DFS; P < 0.001). Similarly, patients with higher ESTIMATE immune scores experienced superior 5- and 10-year OS (P = 0.024) and DFS (P = 0.007). In the training cohort, high abundances of CD8+ TILs were significantly associated with improved 5- and 10-year OS (P = 0.003) and DFS (P = 0.005). These findings were corroborated in an independent validation cohort (n = 84), and combined analysis of the training and validation cohorts [n = 119 (35+84)], which further demonstrated improved 5- and 10-year survival in terms of locoregional control (P < 0.001) and distant metastasis (P = 0.03). Conclusions: Taken together, our study highlights the prognostic value of CD8+ TILs in NPC, and the potential of future investigations into cellular-based immunotherapies employing CD8+ lymphocytes.